Pregnancy interruption using mifepristone (ru-486) a new choice for women in the USA

Journal of Nurse-Midwifery

Volumn 42, Issue 2, 1997, Pages 86-90

  Mackenzie, Susan J ^a   Yeo, Seonae ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABORTIVE AGENT; HORMONE; HORMONE ANTAGONIST; MIFEPRISTONE; MISOPROSTOL; PROSTAGLANDIN; PROSTAGLANDIN DERIVATIVE;

ABORTION, DRUG INDUCED; BIOLOGY; DEVELOPED COUNTRY; DRUG COST; ECONOMICS; ENDOCRINE SYSTEM; FAMILY PLANNING; FEMALE; FERTILITY CONTROL, POSTCONCEPTION; FOOD AND DRUG ADMINISTRATION; HEALTH; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HUMAN; INDUCED ABORTION; LITERATURE REVIEW; METHODOLOGY; NORTH AMERICA; NORTHERN AMERICA; NURSE MIDWIFE; NURSE-MIDWIVES; NURSING; PHYSIOLOGY; PREGNANCY; REVIEW; RU-486; UNITED STATES; WESTERN HEMISPHERE;

ABORTIFACIENT AGENTS; ABORTION, DRUG INDUCED; ABORTION, INDUCED; AMERICAS; BIOLOGY; DELIVERY OF HEALTH CARE; DEVELOPED COUNTRIES; ENDOCRINE SYSTEM; FAMILY PLANNING; FERTILITY CONTROL, POSTCONCEPTION; HEALTH; HEALTH PERSONNEL; HORMONE ANTAGONISTS; HORMONES; LITERATURE REVIEW; MISOPROSTOL; NORTH AMERICA; NORTHERN AMERICA; NURSE-MIDWIVES; PHYSIOLOGY; PROSTAGLANDINS; PROSTAGLANDINS, SYNTHETIC; RU-486; UNITED STATES;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; DRUG COSTS; FEMALE; HUMANS; MIFEPRISTONE; NURSE MIDWIVES; PREGNANCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0031093995     PISSN: 00912182     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-2182(96)00154-1     Document Type: Article

References (32)

1. Summers L. The genesis of the ACNM 1971 statement on abortion. J Nurse Midwifery 1992;37:168-74.
2. ACNM Guidelines. Incorporation of new procedures into nurse-midwifery practice. New York: ACNM, 1992.
3. Baulieu E. Updating RU486 development. Law, Medicine, & Health Care 1992;20:154-6.
4. Spiroff L, Glass R, Case R. Clinical endocrinology & infertility. 5th ed. Baltimore: Williams & Wilkins. 1994:251-89.
5. Moore K, Persaud T. The developing human. 5th ed. Philadelphia: WB Saunders, 1992:25.
6. Spitz IM, Bardin CW. Mifepristone (RU486). A modulator of progestin and glucocorticoid action. N Engl J Med 1993;329:404-11.
7. Creinin MD, Grimes D. Medical options for early abortion. Contemp OB/GYN 1994:185-90.
8. Hill N, Ferguson J, Mackenzie I. The efficacy of oral Mifepristone (RU486) with a prostaglandin E analogue vaginal pessary for the termination of early pregnancy: complications and patient acceptability. Am J Obstet Gynecol 1990;162:414-7.
9. Blackburn ST, Loper DL. Maternal, fetal and neonatal physiology. Philadelphia: WB Saunders, 1992:114-6.
10. Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik, et al. Early pregnancy termination with mifepristone (RU-486) and the orally active prostagiandin (misoprostol). N Engl J Med 1993;328:1509-13
11. Population Council. Medical abortion with mifepristone and misoprostol. New York: ACNM, 1995.
12. Aguillaume CJ, Tyrer LB. Current status and future projections on use of RU486. Contemp OB/GYN 1995;123-40.
13. Lewin T. Legal hurdle cleared in sale of French abortion pill in US. The New York Times 1997 Feb 13; Sect. A:28.
14. Population Council. Status of mifepristone in the United States. New York: ACNM, 1995.
15. Camerson IT, Baird DT. Early pregnancy termination: a comparison between vacuum aspiration and medical abortion using prostaglandin. Br J Obstet Gynaecol 1989;95:271-6.
16. Stubblefield P. Pregnancy termination. In: Gabbe S, Niebyl J, Simpson J, eds. Obstetrics: normal and problem pregnancies. 2nd ed. New York: Churchill Livingstone, 1991:1303-27.
17. Brennan P, Ballard C. Management of complications of first trimester pregnancy termination. In: Mishell D, Brenner P, eds. Management of common problems in obstetrics and gynecology. Boston: Blackwell Scientific Publications, 1994:858-63.
18. Schaffe E, Wortman M, Eisinger S, Franks P. Methotrexate and misoprostol when surgical abortion fails. Obstet Gynecol 1996;87:450-2.
19. Roger M, Baird T. Blood loss following induction of early abortion using mifepristone (RU486) and a prostaglandin analogue (Gemeprost). Contraception 1989;40:439-47
20. Guttmacher Institute. Facts in brief. New York: Alan Guttmacher Institute, 1995.
21. Berer M. Introducing a miscarriage: women centered perspectives on RU-486/prostaglandin as an early abortion method. Law, Medicine & Health Care 1992;20:199-207.
22. Population Council. Highlights from the Population Council presentation advisory committee hearing to the U.S. Food and Drug Administration on mifepristone/misoprostol medical abortion. New York: ACNM, 1996.
23. Turk P. Abortion. In: Lichtman R, Papera S, eds. Gynecology: well women care. East Norwalk, Connecticut: Appleton & Lange, 1989:451-63.
24. Tang GWK, Lau OWK, Yip P. Further acceptability evaluation of RU-486 and ONO 802 as abortifacient agents in a Chinese population. Contraception 1993;48:267-75.
25. Bachelot A, Cludy L, Spira A. Conditions for choosing between drug induced and surgical abortions. Contraception 1992;45:547-59.
26. Thong KJ, Dewer MH, Baird DT. What do women want during medical abortion? Contraception 1992;46:435-42.
27. Hilts P. Trials of French abortion pill begin in United States. New York Times, October 28, 1994.
28. Chalker R, Downer C. A woman's book of choices. 1st ed. New York: Four Walls Eight Windows, 1992:222-3.
29. Cunningham G, MacDonald P, Gant N, Leveno K, Gilstrap L. In: Williams obstetrics 19th ed. Norwalk, Connecticut: Appleton & Lange, 1993:685.
30. National Abortion Federation and The American College of Obstetricians and Gynecologists. Who will provide abortions? Ensuring the availability of qualified practitioners. Washington, DC: National Abortion Federation, 1991.
31. McKee K, Adams E. Nurse midwives' attitudes toward abortion performance and related procedures. J Nurse Midwifery 1994;39:300-11.
32. Fact Finders, Inc. 1995 survey of obstetrician/gynecologists on contraception and unplanned pregnancy: attitudes and practices with regard to abortion. Albany, New York: Kaiser Family Foundation, 1995.